Adalimumab maintains remission in Crohn's diseaseBMJ 2007; 335 doi: http://dx.doi.org/10.1136/bmj.335.7615.325-b (Published 16 August 2007) Cite this as: BMJ 2007;335:325
Patients with moderate to severe Crohn's disease who had achieved remission after a four week regimen of the cytokine inhibitor adalimumab (CLASSIC I trial) went on to a placebo controlled trial …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial